OptiNose Inc (NASDAQ:OPTN) Shares Sold by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS cut its holdings in shares of OptiNose Inc (NASDAQ:OPTN) by 2.2% during the third quarter, HoldingsChannel.com reports. The firm owned 541,690 shares of the company’s stock after selling 12,345 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in OptiNose were worth $3,792,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of OptiNose by 15.9% in the 2nd quarter. BlackRock Inc. now owns 1,918,914 shares of the company’s stock valued at $13,586,000 after acquiring an additional 263,667 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of OptiNose in the 2nd quarter valued at $82,000. Susquehanna International Group LLP acquired a new position in shares of OptiNose in the 2nd quarter valued at $77,000. JPMorgan Chase & Co. increased its position in shares of OptiNose by 6.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,667,724 shares of the company’s stock valued at $17,073,000 after acquiring an additional 163,755 shares during the period. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of OptiNose in the 2nd quarter valued at $72,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:OPTN traded down $0.14 during mid-day trading on Friday, hitting $9.99. The company’s stock had a trading volume of 275,400 shares, compared to its average volume of 191,401. The company has a debt-to-equity ratio of 1.06, a current ratio of 6.60 and a quick ratio of 6.43. OptiNose Inc has a 1 year low of $4.44 and a 1 year high of $11.72. The stock has a market cap of $403.59 million, a price-to-earnings ratio of -3.73 and a beta of 0.63. The business’s fifty day moving average is $7.57 and its two-hundred day moving average is $7.44.

OptiNose (NASDAQ:OPTN) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.66) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.09. OptiNose had a negative net margin of 670.20% and a negative return on equity of 102.10%. The company had revenue of $6.68 million during the quarter, compared to analysts’ expectations of $7.74 million. Analysts anticipate that OptiNose Inc will post -2.79 EPS for the current fiscal year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several equities analysts recently issued reports on OPTN shares. Royal Bank of Canada set a $20.00 target price on OptiNose and gave the company a “buy” rating in a research report on Monday, August 12th. Zacks Investment Research downgraded OptiNose from a “hold” rating to a “sell” rating in a research report on Wednesday, October 16th. BMO Capital Markets lowered their price target on shares of OptiNose from $26.00 to $24.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. Finally, ValuEngine lowered shares of OptiNose from a “buy” rating to a “hold” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $21.50.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

See Also: Golden Cross

Want to see what other hedge funds are holding OPTN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptiNose Inc (NASDAQ:OPTN).

Institutional Ownership by Quarter for OptiNose (NASDAQ:OPTN)

Leave a Reply

Your email address will not be published. Required fields are marked *

*